Compare · BSX vs STSS
BSX vs STSS
Side-by-side comparison of Boston Scientific Corporation (BSX) and Sharps Technology Inc. (STSS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and STSS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $71.85B, about 922.7x STSS ($77.9M).
- BSX has been more active in the news (12 items in the past 4 weeks vs 5 for STSS).
- BSX has more recent analyst coverage (25 ratings vs 0 for STSS).
- Company
- Boston Scientific Corporation
- Sharps Technology Inc.
- Price
- $48.34-1.25%
- $1.84+1.10%
- Market cap
- $71.85B
- $77.9M
- 1M return
- -
- +2.22%
- 1Y return
- -
- -69.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 12
- 5
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Sharps Technology Inc.
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest STSS
- SEC Form 3 filed by new insider Levine Arthur
- Sharps Technology Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer
- Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol "SKYA"; Establishing Category-defining Agentic Finance Platform Serving Global South
- Amendment: SEC Form SCHEDULE 13G/A filed by Sharps Technology Inc.
- Sharps Technology Reports Continued Growth in Q1 2026 Highlighting Strengthened Balance Sheet and Strong Treasury Execution
- Sharps Technology Adopts Limited Duration Stockholder Rights Plan
- SEC Form 10-Q filed by Sharps Technology Inc.
- Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy